Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Evans

Showing results (11-20 of 154) with videos related to

Pageof 16
Sort By:
Current Opinion in Lipidology|June 5, 2002
Therapy and clinical trials: type 2 diabetes: lifestyle and beyondPenny Owen, Marc Evans
Journal of Comparative Effectiveness Research|May 12, 2015
Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practiceMarc Evans, Phil McEwan
Drug Safety|July 26, 2002
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?Marc Evans, Alan Rees
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 4, 2019
A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019Marc Evans, Fernando Ovalle
Expert Opinion on Drug Safety|June 12, 2023
The evolution of real-world evidence in healthcare decision makingDavid M Williams, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 8, 2021
Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome StudiesDavid M Williams, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 26, 2020
Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced TrialsDavid M Williams, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 28, 2020
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?David M Williams, Marc Evans
Current Opinion in Lipidology|May 29, 2004
The metabolic syndrome, inflammation and cardiovascular disease in type 2 diabetesAled W Roberts, Marc Evans
Journal of Nutrition and Metabolism|November 6, 2012
Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological PerspectiveDominique Xavier Brown, Marc Evans
Pageof 16

Showing results (11-20 of 154) with videos related to

Sort By:
Pageof 16
Current Opinion in Lipidology|June 5, 2002
Therapy and clinical trials: type 2 diabetes: lifestyle and beyondPenny Owen, Marc Evans
Journal of Comparative Effectiveness Research|May 12, 2015
Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practiceMarc Evans, Phil McEwan
Drug Safety|July 26, 2002
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?Marc Evans, Alan Rees
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 4, 2019
A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019Marc Evans, Fernando Ovalle
Expert Opinion on Drug Safety|June 12, 2023
The evolution of real-world evidence in healthcare decision makingDavid M Williams, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 8, 2021
Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome StudiesDavid M Williams, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 26, 2020
Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced TrialsDavid M Williams, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 28, 2020
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?David M Williams, Marc Evans
Current Opinion in Lipidology|May 29, 2004
The metabolic syndrome, inflammation and cardiovascular disease in type 2 diabetesAled W Roberts, Marc Evans
Journal of Nutrition and Metabolism|November 6, 2012
Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological PerspectiveDominique Xavier Brown, Marc Evans
Pageof 16